


## Supplementary Figure 10



**Supplementary Figure 10 (related to Figure 7). Impairment of CSC agrin is sufficient to impair PDAC growth in an orthotopic cell line model. (A)** Experimental layout (related to figure 7A): to impair agrin expression in specific cancer cell subpopulations, CSC and NSCC were sorted from the MIA PaCa-2 Tet-Off shAgrin/shScramble clones, and then orthotopically implanted into the pancreas of Rag2<sup>-/-</sup>Il2rg<sup>-/-</sup> mice. In this case, both groups are treated with doxycycline, therefore both groups express normal levels of Agrin. **(B)** Tumor growth curve measured by ultrasound of doxycycline treated CSC from MIA PaCa-2 Tet-Off shAgrin with NSCC from MIA PaCa-2 Tet-Off shScramble tumors (injected at the same percentages found in the cells of origin; n=7), and doxycycline treated NSCC from MIA PaCa-2 Tet-Off shAgrin with CSC from MIA PaCa-2 Tet-Off shScramble tumors (injected at the same percentages found in the cells of origin; n=6; two-way anova). **(C)** Quantification of tumor growth using the last ultrasound measurement of pancreas tumors in doxycycline treated (WT) or untreated (KD) CSC from MIA PaCa-2 Tet-Off shAgrin with NSCC from MIA PaCa-2 Tet-Off shScramble group and doxycycline treated (WT) or untreated (KD) NSCC from MIA PaCa-2 Tet-Off shAgrin with CSC from MIA PaCa-2 Tet-Off shScramble group (left to right, paired t-test, \* $p < 0.05$ ). **(D)** Schematic representation of Agrin allele recombination and representative photo of an agarose gel with the results of a PCR of Agrin<sup>fl/fl</sup> allele recombination in pancreatic tumors of KPC and KPAC. **(E)** Representative photos of the colorimetric assay (left) and representative brightfield photos (right) of PDX cells treated ex vivo with anti-agrin blocking antibody (Mab5204 10 $\mu$ g/mL), IgG (10 $\mu$ g/mL) or untreated.